These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 18021219)

  • 1. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion.
    Koon EC; Ma PC; Salgia R; Welch WR; Christensen JG; Berkowitz RS; Mok SC
    Int J Gynecol Cancer; 2008; 18(5):976-84. PubMed ID: 18021219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma.
    Kim HJ; Yoon A; Ryu JY; Cho YJ; Choi JJ; Song SY; Bang H; Lee JS; Cho WC; Choi CH; Lee JW; Kim BG; Bae DS
    Sci Rep; 2016 Dec; 6():38502. PubMed ID: 27917934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma.
    Kenessey I; Keszthelyi M; Krámer Z; Berta J; Adám A; Dobos J; Mildner M; Flachner B; Cseh S; Barna G; Szokol B; Orfi L; Kéri G; Döme B; Klepetko W; Tímár J; Tóvári J
    Curr Cancer Drug Targets; 2010 May; 10(3):332-42. PubMed ID: 20370683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-Met is a potentially new therapeutic target for treatment of human melanoma.
    Puri N; Ahmed S; Janamanchi V; Tretiakova M; Zumba O; Krausz T; Jagadeeswaran R; Salgia R
    Clin Cancer Res; 2007 Apr; 13(7):2246-53. PubMed ID: 17404109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of critical role of c-Met and its inhibitor SU11274 in colorectal carcinoma.
    Gao W; Bing X; Li M; Yang Z; Li Y; Chen H
    Med Oncol; 2013 Jun; 30(2):546. PubMed ID: 23536000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
    Ma PC; Jagadeeswaran R; Jagadeesh S; Tretiakova MS; Nallasura V; Fox EA; Hansen M; Schaefer E; Naoki K; Lader A; Richards W; Sugarbaker D; Husain AN; Christensen JG; Salgia R
    Cancer Res; 2005 Feb; 65(4):1479-88. PubMed ID: 15735036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274.
    Hou J; Dong J; Sun L; Geng L; Wang J; Zheng J; Li Y; Bridge J; Hinrichs SH; Ding SJ
    J Transl Med; 2011 May; 9():64. PubMed ID: 21575221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined γ-tocotrienol and Met inhibitor treatment suppresses mammary cancer cell proliferation, epithelial-to-mesenchymal transition and migration.
    Ayoub NM; Akl MR; Sylvester PW
    Cell Prolif; 2013 Oct; 46(5):538-53. PubMed ID: 24033536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth.
    Inagaki Y; Qi F; Gao J; Qu X; Hasegawa K; Sugawara Y; Tang W; Kokudo N
    Biosci Trends; 2011; 5(2):52-6. PubMed ID: 21572247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of c-Met inhibitor SU11274 on human colon cancer cell growth.
    Gao SH; Liu C; Wei J; Feng Y
    Chin Med J (Engl); 2013 Jul; 126(14):2705-9. PubMed ID: 23876900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.
    Berthou S; Aebersold DM; Schmidt LS; Stroka D; Heigl C; Streit B; Stalder D; Gruber G; Liang C; Howlett AR; Candinas D; Greiner RH; Lipson KE; Zimmer Y
    Oncogene; 2004 Jul; 23(31):5387-93. PubMed ID: 15064724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.
    Sattler M; Pride YB; Ma P; Gramlich JL; Chu SC; Quinnan LA; Shirazian S; Liang C; Podar K; Christensen JG; Salgia R
    Cancer Res; 2003 Sep; 63(17):5462-9. PubMed ID: 14500382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MET oncogene inhibition as a potential target of therapy for uveal melanomas.
    Abdel-Rahman MH; Boru G; Massengill J; Salem MM; Davidorf FH
    Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3333-9. PubMed ID: 20164465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homeobox gene HLX is a regulator of HGF/c-met-mediated migration of human trophoblast-derived cell lines.
    Rajaraman G; Murthi P; Brennecke SP; Kalionis B
    Biol Reprod; 2010 Oct; 83(4):676-83. PubMed ID: 20554918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
    Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
    Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death.
    Lui VW; Wong EY; Ho K; Ng PK; Lau CP; Tsui SK; Tsang CM; Tsao SW; Cheng SH; Ng MH; Ng YK; Lam EK; Hong B; Lo KW; Mok TS; Chan AT; Mills GB
    Oncogene; 2011 Mar; 30(9):1127-34. PubMed ID: 21057531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CUL4B promotes aggressive phenotypes of renal cell carcinoma via upregulating c-Met expression.
    Chen S; Wang Y; Chen L; Xia Y; Cui J; Wang W; Jiang X; Wang J; Zhu Y; Sun S; Zou Y; Gong Y; Shi B
    Int J Biochem Cell Biol; 2021 Jan; 130():105887. PubMed ID: 33227394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recruited T cells promote the bladder cancer metastasis via up-regulation of the estrogen receptor β/IL-1/c-MET signals.
    Tao L; Qiu J; Slavin S; Ou Z; Liu Z; Ge J; Zuo L; Guancial EA; Messing EM; Chang C; Yeh S
    Cancer Lett; 2018 Aug; 430():215-223. PubMed ID: 29684419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. с-Met receptor can be activated by extracellular alkaline medium.
    Serova OV; Orsa AN; Chachina NA; Petrenko AG; Deyev IE
    J Recept Signal Transduct Res; 2019 Feb; 39(1):67-72. PubMed ID: 31215287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule inhibitor of c-Met (PHA665752) suppresses the growth of ovarian cancer cells and reverses cisplatin resistance.
    Li E; Hu Z; Sun Y; Zhou Q; Yang B; Zhang Z; Cao W
    Tumour Biol; 2016 Jun; 37(6):7843-52. PubMed ID: 26695152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.